Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:http://oc1dean.blogspot.com/2010/11/my-background-story_8.html

Wednesday, August 2, 2017

Silk Road raises $47M to grow stroke-prevention business

Talk to your doctor about the dangers of stroke due to the endarterectomy procedure and why you would want to put inflexible metal stents in flexible arteries. Don't listen to me, but ask your doctor plenty of questions.   Ask for a guarantee of no stroke due to any procedure.
http://www.fiercebiotech.com/medtech/silk-road-raises-47m-to-grow-stroke-prevention-business?
by Nick Paul Taylor |
Silk Road Medical has raised $47 million to commercialize its stroke-prevention devices in the U.S. and overseas. The funding positions Silk Road to build on approvals and reimbursement nods it has picked up on both sides of the Atlantic for its transcarotid artery revascularization (TCAR) devices.
New investors Norwest Venture Partners and Janus Capital Management led the round with the support of existing backers Warburg Pincus, The Vertical Group and CRG. Silk Road persuaded the syndicate to invest $47 million less than two years after it tapped some of the same investors for $57 million on the strength of its potential to corner a big, emerging medical device market.
Sunnyvale, California-based Silk Road has built its nascent business upon products that facilitate the TCAR surgical procedure. TCAR is used to treat carotid artery blockages that could cause strokes. The first step is to direct blood flow in the carotid artery away from the brain. Once this is done, surgeons can insert a stent into the carotid artery to stabilize the plaque without putting the brain at risk of fragments that may come loose during the procedure.
Silk Road’s Enroute product line covers both steps in this process. The Enroute Transcarotid Neuroprotection System takes blood from the carotid artery, filters it and returns it to the body via the leg. While this system is in place, surgeons can insert the Enroute Transcarotid Stent System.
Silk Road has won approvals for the devices on the strength of data linking the system to a 1.4% 30-day all stroke rate. And in doing so has attracted the attention of a growing pool of investors.
"TCAR is an elegant, patient-friendly approach that has really resonated with physician leaders in the field. I have followed the company and its progress for years and have been pleased to see their rapid FDA approvals and favorable reimbursement decisions,” Norwest Venture Partners’ Robert Mittendorff, M.D. said in a statement.
The challenge now is to turn first-mover status in the transcarotid sector into sales that justify the amount of money investors have pumped into Silk Road. The $47 million investment is intended to support this effort by equipping Silk Road to build out its commercial infrastructure in the U.S. while targeting markets overseas.

No comments:

Post a Comment